Troutman Pepper counseled Cagent Vascular Inc., a rapidly growing commercial stage medical device company, in a Series C Preferred Stock Financing which raised in excess of $30M. The funds will be used to accelerate U.S. market adoption and to expand the product portfolio of the Serranator PTA Serration Balloon Catheter. Read a company press release about the transaction.
Cagent Vascular, founded and led by serial medical technology entrepreneurs, is the leader in Serration Technology to treat peripheral artery disease. The company has developed a transformative improvement to conventional angioplasty, which is the most commonly performed procedure to restore blood flow. Although angioplasty has been used clinically for over 50 years, there remain significant opportunities to optimize the therapy and to improve the treatment outcomes of cardiovascular disease.
The Troutman Pepper team advising Cagent Vascular is led by Chris Miller and included Stephen Fox,Jenny Ji, Jake McDonough, Safvet Besen and Dawn Hall.
Since its formation, Cagent Vascular has been a participant in Troutman Pepper’s SEED Program, which combines the resources of an experienced, multidisciplinary team into an affordable package for startups, early-stage, and fast-growing companies. Clients receive legal counsel, mentoring, relationship-building opportunities, and more.
The firm regularly advises startup, emerging growth and venture capital clients through every stage of their life cycle. Industries served span software, hardware and other high-technology, biotechnology, pharmaceuticals and medical devices, financial technology, health care, consumer products, food and beverage, media and telecommunications products and services, and many others.
Original source can be found here.